Direct application of BDNF into the perilymph via a drug-delivering cannula integrated into the implant [10] has been shown to increase SGN survival, but due to the associated risks (such as infection, increased risk of shearing-induced damage, limitations on flow rate) [11], this method is only viable for a comparably short period of time. The gene discussed is BDNF; the disease is infection.